10% off everything · from Tuesday until Sunday midnight
All peptides
RestockedRetatrutide 10mg / 20mg / 30mg / 40mg / 60mg research peptide vial — buy Retatrutide 10mg / 20mg / 30mg / 40mg / 60mg UK | Peptides UK 4U
Weight & Metabolic

Retatrutide 10mg / 20mg / 30mg / 40mg / 60mg

Also known as Reta

Investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 20mg, 30mg, 40mg and 60mg lyophilised vials at 99%+ purity for in vitro research.

Size
How would you like it prepared?
Vial
Best value · Dispatch within 48 hours
Lowest cost per mg — you reconstitute it yourself
£44.99 – £188.99
Pre-filled Replacement Cartridge
Made to order · +£12.99
Refill only — you must already own a Quick Pen
from £56.68

Best value and fastest option — supplied as a lyophilised vial, shipped within 48 hours of ordering. Use our calculator for your target concentration.

£49.99 – £209.99£44.99 – £188.99

For In Vitro Use Only — Not for Human Use

Lab-Verified Purity
View COAs
99%+
HPLC purity
Mass-Spec
Identity verified
Batch CoA
Independent lab

Every batch is independently HPLC & mass-spec tested. Certificate of Analysis is batch-numbered and matched to the vial you receive.

Verified customer WhatsApp support group
Invite-only. Your personal invite link is sent automatically with your shipping confirmation after your first order — please don't message us to request it. Reconstitution help, batch COAs and protocol guidance.
99%+ HPLC purity
Tracked · ships within 48h
UK-registered Ltd
WhatsApp support

Overview

Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder in 20mg, 30mg, 40mg and 60mg vials, each batch is verified to 99%+ purity by RP-HPLC and mass spectrometry.

Research

Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.

View basket0Checkout